ATH net loss up 93% to A$23.4M; Phase 3 ATH434 on track
ATH reported net loss increased 93% to A$23.4M as R&D and admin costs rose, while its Phase 3 ATH434 trial is on track.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.